Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD5044 in Patients With Mixed Dyslipidemia
NCT06797401Phase 2Recruiting
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Jan 2025
- Primary completion
- May 2027
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rbd5044 in mixed dyslipidemia (3 arms), sponsored by Ribocure Pharmaceuticals AB. Primary endpoint: Change from baseline in triglyceride levels at 16 weeks. Started Jan 2025; status: recruiting.
02
Drugs
rbd5044
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT06797401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797401.